title: Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer.
abstract: Oxaliplatin plays a key role in the treatment of advanced colorectal cancer. The dose-limiting side effect of this platinum analogue is neurotoxicity. Significant efforts have been undertaken in an attempt to prevent and/or circumvent the development of neurotoxicity. Sodium channel inactivation kinetics on rat sensory sural nerve preparations are altered after exposure to oxaliplatin. Carbamazepine antagonizes this effect in vitro. Results from preliminary clinical studies indicate that the sodium channel blockers carbamazepine and gabapentin may be effective in preventing neurotoxicity. The role of amifostine is not yet clear. Randomized clinical studies are necessary to confirm the potential benefit of carbamazepine and other sodium channel blockers in preventing and/or overcoming the development of oxaliplatin-induced neurotoxicity.
authors.affiliation: II. Medical Hospital and Health Center, Technischen Universität München, Klinikum rechts der Isar, Ismaninger St 22, 81675 Munich, Germany. christian.lersch@lrz.tum.de
authors.forename: Christian
authors.initials: C
authors.lastname: Lersch
authors.forename: Renate
authors.initials: R
authors.lastname: Schmelz
authors.forename: Florian
authors.initials: F
authors.lastname: Eckel
authors.forename: Johannes
authors.initials: J
authors.lastname: Erdmann
authors.forename: Martina
authors.initials: M
authors.lastname: Mayr
authors.forename: Ewert
authors.initials: E
authors.lastname: Schulte-Frohlinde
authors.forename: Stefan
authors.initials: S
authors.lastname: Quasthoff
authors.forename: Julian
authors.initials: J
authors.lastname: Grosskreutz
authors.forename: Helmuth
authors.initials: H
authors.lastname: Adelsberger
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002220:Carbamazepine / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D006801:Humans; D066298:In Vitro Techniques; D020258:Neurotoxicity Syndromes / Q000517:prevention & control*; D009944:Organoplatinum Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D000077150:Oxaliplatin; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced / Q000517:prevention & control*; D051381:Rats; D026941:Sodium Channel Blockers / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D026941:Sodium Channel Blockers; D000077150:Oxaliplatin; D002220:Carbamazepine